Australia Stock Exchange release from IMUGENE : Dose Escalation in Phase 1 Clinical Trial of CHECKvacc
23/03/2022 22:15
Australia Stock Exchange release from IMUGENE IMU.AX : Dose Escalation in Phase 1 Clinical Trial of CHECKvacc
Recent news on Imugene
See all newsAustralia's Imugene rises on fresh responses in blood cancer drug trial
Brief: Imugene Ltd Says Leslie Chong Resigns As CEO
Australia's Imugene loses most in over 8-years on discounted placement
Brief: Imugene To Raise A$11.12 Million Via Placement At A$0.095 Per Share
Brief: Imugene Requests Trading Halt Pending Proposed Capital Raising Announcement